Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Pseudogene similar to part of ribosomal protein L18a LOC100136354" (ENSG00000248895) is a processed pseudogene derived from the ancestral ribosomal protein L18a (RPL18A) gene[7][1][3]. Pseudogenes are defined as DNA sequences similar to known genes but generally incapable of encoding functional proteins due to crippling mutations, truncation, or loss of regulatory elements[2][1]. Many ribosomal protein genes, including RPL18A, have numerous processed pseudogenes in the human genome produced by retrotransposition[4][1][6]. These pseudogenes typically do not produce proteins but may be transcribed and can sometimes affect gene regulation, for example by acting as microRNA decoys, producing non-coding RNAs, or rarely being translated into small peptides[1][9][5]. There is no evidence or precedent for this pseudogene being a direct therapeutic target, encoding a functional protein, or playing a defined role in disease or drug action. Notes on structure and naming: - The entity is not a functional gene or protein; it is a pseudogene sharing sequence similarity with RPL18A[7][3]. - RPL18A is a protein-coding gene encoding 60S ribosomal protein L18a, but ENSG00000248895 is a non-functional, processed pseudogene[6][8]. - No standard abbreviation for this pseudogene exists, and its designation is strictly as a pseudogene. - There is no established role as a receptor, enzyme, transporter, or any other class of druggable target. - Presence of the term "LOC100136354" and inconsistent nomenclature further mark this as a non-canonical, potentially outdated or low-utility entry[7]. Summary judgment: This is a **pseudogene** with no protein-coding potential, no established biological or therapeutic relevance, and is **not considered a therapeutic target**. Its inclusion as a target is **incorrect**. The entry has too little information for structured therapeutic annotation and should be flagged for review or exclusion[7][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to part of ribosomal protein L18a LOC100136354.